{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-032948","form_type":"8-K","ticker":"PLUR","cik":"0001158780","company_name":"Pluri Inc.","filed_at":"2025-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.662672+00:00","generated_at":"2026-05-23T11:33:53.191575+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pluri's subsidiary loses $4.2M NIAID contract for PLX-R18 H-ARS therapy; termination for convenience effective April 15","bullets":["Pluri Biotech Ltd. received termination notice from NIAID for a $4.2M contract awarded July 2023 to develop PLX-R18 for Hematopoietic Acute Radiation Syndrome.","Termination effective April 15, 2025, for the government's convenience; Pluri links it to broader federal budgetary adjustments affecting NIH.","Contract involved collaboration with AFRRI and USUHS; company is monitoring potential implications for other programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-032948","json":"https://secwatch.observer/filing/0001213900-25-032948.json","markdown":"https://secwatch.observer/filing/0001213900-25-032948.md","text":"https://secwatch.observer/filing/0001213900-25-032948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1158780/000121390025032948/0001213900-25-032948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1158780/000121390025032948/ea0238672-8k_pluri.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T11:33:53.191575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}